---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-003321"
form_type: "8-K"
ticker: "GKOS"
cik: "0001192448"
company_name: "GLAUKOS Corp"
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:34:04.370714+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Glaukos reports preliminary Q4 2025 net sales ~$143M (+36% YoY); reaffirms FY2026 guidance $600-620M

## Summary
- Q4 2025 net sales ~$143M (+36% YoY); FY2025 net sales ~$507M (+32% YoY).
- U.S. Glaucoma net sales FY2025 $299M, including iDose TR $136M; Corneal Health $86M.
- Cash & equivalents $283M, no debt at Q4 end; 2026 revenue guidance reaffirmed $600-620M.
- International Glaucoma net sales FY2025 $122M; Q4 alone ~$33M.
- Company will report full Q4 & FY2025 results on Feb 17, 2026.

## SEC filing metadata
- accession: 0001104659-26-003321
- form_type: 8-K
- ticker: GKOS
- cik: 0001192448
- company_name: GLAUKOS Corp
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1192448/000110465926003321/0001104659-26-003321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1192448/000110465926003321/gkos-20260113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-003321
- JSON: https://secwatch.observer/filing/0001104659-26-003321.json
- Plain text: https://secwatch.observer/filing/0001104659-26-003321.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.